Der interessante Fall – Therapiesequenzen im klinischen Alltag

Gampenrieder, SP; 8. Interdisziplinärer Mammadiskurs; 24.10.2014; Wien. 2014.

Excellent response of lupus hepatitis to mycophenolate mofetil: a case report

Psenak, O; Studnicka-Benke, A; Haufe, H; Greil, R; _x000D_ 10th CECR Congress; 06.-07.12.2014; Wien. 2014.

Prädiktive Faktoren für Bevacizumab beim Mammakarzinom

Gampenrieder, SP; ABCSG Jahrestagung; 07.11.2014; Saalfelden. 2014.

Highlights von Donnerstagnachmittag und Freitagnachmittag

Gampenrieder, SP; 1. Post-SABCS 2013; 10.01.2014; Wien. 2014.

Das triple-negative Mammakarzinom: eine therapeutische Herausforderung

Gampenrieder, SP; ÖGHO Frühjahrstagung; 11.04.2014; Innsbruck. 2014.

T-DM1

GAMPENRIEDER, SP; GREIL, R; MARTH, C; PETRU, E; RINNERTHALER, G; STEGER, GG ArzneimittelPROFIL T-DM1, Juli 2014. 2014.

The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by „on-demand“ addition of plerixafor to granulocyte-colony-stimulating factor.

Girbl, T; Lunzer, V; Greil, R; Namberger, K; Hartmann, TN TRANSFUSION. 2014; 54(9): 2325-2335.

CLL cells under flow.

Hartmann, TN BLOOD. 2014; 123(23): 3533-3534.

Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).

Kocher, F; Pircher, A; Mohn-Staudner, A; Romeder, F; Duller, W; Steinmaurer, M; Eckmayr, J; Schmid, T; Hilbe, W; Fiegl, M; Greil, R LUNG CANCER. 2014; 85(3): 395-400.

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.

Pleyer, L; Burgstaller, S; Girschikofsky, M; Linkesch, W; Stauder, R; Pfeilstocker, M; Schreder, M; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Krippl, P; Geissler, D; Voskova, D; Schlick, K; Thaler, J; Machherndl-Spandl, S; Theiler, G; Eckmüllner, O; Greil, R; ANN HEMATOL. 2014; 93(11): 1825-1838.